The Moment Study: Mixed Method E-cigarette Study

The universe of tobacco products is expanding, with new noncombustible products gaining popularity even as the reduction in prevalence of cigarette smoking slows or stalls. E-cigarettes, or Electronic Nicotine Delivery Systems (ENDS), are the most prevalent of these emerging noncombustible products. With sales increasing rapidly and more efficient pulmonary delivery devices under development, ENDS are likely to play an increasing role in the future tobacco market. Little is known about the cognitions and behaviors leading to or sustaining ENDS use. Smokers may use ENDS to subvert smoking restrictions, to reduce perceived smoking harms, or for smoking cessation. Evidence about ENDS use is emerging from national surveillance and laboratory research, but the majority of information on ENDS is limited to retrospective surveys and convenience samples of White male ENDS users. The investigators research suggests Black smokers are less likely than White smokers to try and be current ENDS users, perhaps due to a greater degree of perceived harm associated with ENDS, a preference for menthol, or cultural norms. Thus, it is timely and critical to study how all smokers, including Blacks and menthol smokers, experience and initiate ENDS use employing valid, innovative research methods.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Smoking Behavior

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

American Legacy Foundation

Washington D.C., District of Columbia, 20036, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants must:

be aged 18 years or older
reside in Washington, D.C. metro area (including VA and MD suburbs)
be proficient in English
be daily smoker with at least 5 years of established daily smoking

A person will be categorized as a daily smoker if he reports daily smoking of at least 8 cigarettes a day for the past 5 years, and records an exhaled air carbon monoxide (CO) level > 8 parts-per-million (ppm) at the baseline in-person meeting.
Daily smokers will be eligible for the main study if they do not intend to quit in the next 30 days.
If they do intend to quit in the next 30 days, eligible daily smokers will be enrolled in the second arm of the study.
not taking smoking cessation medications;
smoked LCC/cigars/hookah less than 5 times in last 30 days
have not used other tobacco products in last 30 days
have not used an ENDS product (electronic cigarette) in the last 30 days
be interested in trying an ENDS
have an iPhone or Android that allows installation of applications and use it daily
have a phone plan that allows unlimited text messages
be willing to travel to the data collection cite four times in three weeks
not be breastfeeding or planning to become pregnant
not have heart disease/uncontrolled blood pressure
not have psychosis/suicidal thoughts
not be currently enrolled in an alcohol treatment program
not be out of town for more than 5 nights in the next 6 weeks

Exclusion criteria

Individuals who do not satisfy the criteria above will not be eligible for this study.
There will be no involvement of vulnerable populations.

Treatment and study plan

Ecig group 1

Other

E-cigarettes were 3% nicotine and of tobacco or menthol flavor, depending on participants' usual flavor preference.

Primary outcomes

Cigarette Use

Time frame: Study Day 7, Week 2

Change in the average number of cigarettes per day comparing average cigarettes per day on study day 6 (last day of cigarette-only use) to average cigarettes per day on study day 7 (first day of e-cigarette and cigarette use).

Sponsors and collaborators

Lead sponsor

Truth Initiative

Other

Registry information

Official study title

A Mixed Method EMA Assessment of Cognition and Behavior Among New ENDS Users: An Observational Cohort Study

Acronym: Moment

Important dates

Study start: 2014
Primary completion: 2016
Study completion: 2016
First posted: Oct 10, 2014
Registry last updated: May 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed